Treatment satisfaction and quality of life in patients treated with fingolimod

References

• FoulonSMauraGDalichamptMPrevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance dataJ Neurol201726461185119228516332
   PubMed Web of Science ®Google Scholar
• LublinFDReingoldSCCohenJADefining the clinical course of multiple sclerosis: the 2013 revisionsNeurology201483327828624871874
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• IvanovaJIBirnbaumHGSamuelsSDavisMPhillipsALMeleticheDThe cost of disability and medically related absenteeism among employees with multiple sclerosis in the USPharmacoeconomics200927868169119712010
   PubMed Web of Science ®Google Scholar
• MichalskiDLiebigSThomaeESingerSHinzABerghFTAnxiety, depression and impaired health-related quality of life are therapeutic challenges in patients with multiple sclerosisMental Illness201021e525478088
   PubMedGoogle Scholar
• ClavelouPAuclairCTaitheFGerbaudLQuality of life in multiple sclerosis: theoretical and practical aspectsRev Neurologique2009165Spec2F115F124
   Google Scholar
• GiovannoniGSouthamEWaubantESystematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherenceMult Scler201218793294622249762
   PubMed Web of Science ®Google Scholar
• BonafedeMMJohnsonBHWentenMWatsonCTreatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United StatesClin Ther201335101501151224139422
   PubMed Web of Science ®Google Scholar
• JokubaitisVGSpelmanTLechner-ScottJThe Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multi-centre study of drug utilisation using the MSBase platformPLoS One201383e5969423527252
   PubMed Web of Science ®Google Scholar
• ReynoldsMWStephenRSeamanCRajagopalanKPersistence and adherence to disease modifying drugs among patients with multiple sclerosisCurr Med Res Opin201026366367420070144
   PubMed Web of Science ®Google Scholar
• ZhornitskySGreenfieldJKochMWLong-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyPLoS One2015104e012382425867095
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2011181697720561039
   PubMed Web of Science ®Google Scholar
• ScottLJFingolimod: a review of its use in the management of relapsing-remitting multiple sclerosisCNS Drugs201125867369821790210
   PubMed Web of Science ®Google Scholar
• VermerschPCzlonkowskaAGrimaldiLMTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMulti Scler2014206705716
   PubMed Web of Science ®Google Scholar
• CalkwoodJCreeBCraytonHImpact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialBMC Neurol20141422025424122
   PubMed Web of Science ®Google Scholar
• BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adher201263948
   PubMed Web of Science ®Google Scholar
• AlbrechtGHoogstratenJSatisfaction as a determinant of complianceCommunity Dent Oral Epidemiol19982621391469645408
   PubMed Web of Science ®Google Scholar
• GlanzBIMusallamARintellDJChitnisTWeinerHLHealyBCTreatment satisfaction in multiple sclerosisInt J MS Care2014162687525061430
   PubMedGoogle Scholar
• Al-JabiSWZyoudSHSweilehWMRelationship of treatment satisfaction to health-related quality of life: findings from a cross-sectional survey among hypertensive patients in PalestineHealth Expect20151863336334825484002
   PubMed Web of Science ®Google Scholar
• NicolucciACucinottaDSquatritoSClinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetesNutr Metab Cardiovasc Dis2009191455318450436
   PubMed Web of Science ®Google Scholar
• TurnerRRTestaMAHayesJFSuMValidation of the allergic rhinitis treatment satisfaction and preference scaleAllergy Asthma Proc201334655155724079817
   PubMed Web of Science ®Google Scholar
• AtkinsonMJSinhaAHassSLValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes200421214987333
   PubMedGoogle Scholar
• EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy199016319920810109801
   PubMed Web of Science ®Google Scholar
• GolinCEDiMatteoMRGelbergLThe role of patient participation in the doctor visit. Implications for adherence to diabetes careDiabetes Care19961910115311648886566
   PubMed Web of Science ®Google Scholar
• de SezeJBorgelFBrudonFPatient perceptions of multiple sclerosis and its treatmentPatient Prefer Adher20126263273
   PubMed Web of Science ®Google Scholar
• TintoréMAlexanderMCostelloKThe state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfactionPatient Prefer Adher2017113345
   Web of Science ®Google Scholar
• ColpaertMHA therapeutic education programme for patients with multiple sclerosisMulti Scler201016SupplS170S171
   Google Scholar
• RieckmannPBoykoACentonzeDAchieving patient engagement in multiple sclerosis: a perspective from the multiple sclerosis in the 21st Century Steering GroupMulti Scler Relat Disord201543202218
   PubMed Web of Science ®Google Scholar
• TingJLiuYPetrilloJGiannattasioGSabatellaGTreatment satisfaction with disease modifying therapies in multiple sclerosis: a systematic review of studies using the Treatment Satisfaction Questionnaire for Medication (Tsqm)Value Health2015187A760A761
   Web of Science ®Google Scholar
• SaizAMoraSBlancoJTherapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE StudyNeurologia201530421422224484756
   PubMed Web of Science ®Google Scholar
• HaaseRKullmannJSZiemssenTTherapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS surveyTher Adv Neurol Disord20169425026327366231
   PubMed Web of Science ®Google Scholar
• HansonKAAgashivalaNStringerSMBalantacZBrandesDWA cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimodPatient Prefer Adher20137309318
   Web of Science ®Google Scholar
• PernegerTVCombescureCCourvoisierDSGeneral population reference values for the French version of the EuroQol EQ-5D health utility instrumentValue Health201013563163520412541
   PubMed Web of Science ®Google Scholar
• DozMChouaidCCom-RuelleLThe association between asthma control, health care costs, and quality of life in France and SpainBMC Pulm Med2013131523517484
   PubMed Web of Science ®Google Scholar
• VexiauPMavrosPKrishnarajahGLyuRYinDHypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in FranceDiabetes Obes Metab200810Suppl 11624
   PubMed Web of Science ®Google Scholar
• TouboulCAmatePBallesterMBazotMFauconnierADaraiEQuality of life assessment using EuroQOL EQ-5D questionnaire in patients with deep infiltrating endometriosis: the relation with symptoms and locationsInt J Chronic Dis2013201345213426464845
   PubMedGoogle Scholar
• HershCMHara-CleaverCRudickRACohenJABermelRAOntanedaDExperience with fingolimod in clinical practiceInt J Neurosci2015125967868525271798
   PubMed Web of Science ®Google Scholar
• AhmadHTaylorBVvan der MeiIThe impact of multiple sclerosis severity on health state utility values: evidence from AustraliaMulti Scler201723811571166
   Web of Science ®Google Scholar
• OrmeMKerriganJTyasDRussellNNixonRThe effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UKValue Health2007101546017261116
   PubMed Web of Science ®Google Scholar
• ReeseJPWienemannGJohnAPreference-based health status in a German outpatient cohort with multiple sclerosisHealth Qual Life Outcomes20131116224089999
   PubMed Web of Science ®Google Scholar
• MitchellAJBenito-LeonJGonzalezJMRivera-NavarroJQuality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeingLancet Neurol20054955656616109362
   PubMed Web of Science ®Google Scholar
• MontalbanXComiGO’ConnorPOral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II studyMulti Scler2011171113411350
   PubMed Web of Science ®Google Scholar
• CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
   PubMed Web of Science ®Google Scholar
• FoxEEdwardsKBurchGOutcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMulti Scler Relat Disord201435607619
   PubMed Web of Science ®Google Scholar